SLC6A4 Polymorphisms and Age of Onset in Late-life Depression on Treatment Outcomes with Citalopram: A Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Report  

Oleh:

Shiroma, R. Paulo ; Drews, Maureen S. ; Geske, Jennifer R. ; Mrazek, David A.

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The American Journal of Geriatric Psychiatry (keterangan: ada di ClinicalKey) vol. 22 no. 11 (Nov. 2014), page 1140-1148.
Topik: depression; citalopram; sequenced treatment alternatives; to relieve depression (STAR*D); SLC6A4

Ketersediaan

Perpustakaan FK Nomor Panggil: A35.K Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective Age at onset of first major depressive episode (MDE) does not necessarily translate into different treatment outcomes to antidepressants in late-life depression. The influence of genetic variants may affect this relationship. Design Post hoc data set analysis of the association between variants in the promoter region (indel, rs25531) and within intron 2 (Stin2 VNTR) of the SCL6A4 gene and treatment outcomes among older participants in the first treatment arm of the Sequenced Treatment Alternatives to Relieve Depression trial (STAR*D). Setting Participants were enrolled from 23 psychiatric and 18 primary care settings. Participants Two hundred twenty-one, white non-Hispanic subjects, aged 60 to 75 years, with 16-item Quick Inventory of Depressive Symptomatology-Clinician Rating (QIDS-CR16) initial score =10, and who remained in the study for at least 6 weeks, were genotyped. Intervention Citalopram treatment for up to 14 weeks. Measurements Main outcome was remission rate defined as a score of =5 on the QIDS-CR16. Response was a secondary outcome defined as a reduction of =50% of baseline QIDS-CR16. Results Polymorphism in the indel promoter region was associated with remission among subjects whose first lifetime episode of major depression occurred later than age 55. In this group, subjects with L/L genotype had significantly higher remission (80% versus 43%) compared to those subjects with any other indel promoter genotype. Multivariate analysis demonstrated that the genetic effect of the indel promoter region on remission increases along with age at onset of MDE. Conclusions Variants in the indel promoter region of the SLC6A4 gene have a more robust effect to antidepressant outcome among older subjects who experienced their first MDE at a later age. The mechanism of action of these variants remains to be determined.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali